Cybersecurity incidents in healthcare and life sciences are no longer rare events. They are becoming part of a larger pattern. Organizations that handle patient information, research data, intellectual property, clinical records, proprietary formulas, operational systems, and regulated data are increasingly attractive targets for cybercriminals. The recent Amgen cybersecurity breach is another reminder of how serious this risk has become.

For healthcare organizations, biotech companies, pharmaceutical firms, medical practices, research organizations, and any business entrusted with sensitive information, the lesson is clear: the data you store is valuable, and attackers know it.

The Value of  Healthcare and Biotech Data

Healthcare and biotech organizations hold a unique combination of sensitive data. Unlike some industries that mainly store financial records or customer contact information, healthcare and life sciences companies often maintain highly personal, highly regulated, and highly valuable data all at once. Records include billing, medical history, and even intellectual property. For attackers, this data can be valuable for extortion, resale, competitive intelligence, fraud, or strategic misuse. That combination of patient trust, regulated information, and proprietary research makes the healthcare and biotech sectors high-value targets.

The Amgen incident involved cloud storage systems hosted by external service providers, according to the reporting. That detail matters because many organizations now rely on cloud platforms to store and manage sensitive information. Cloud systems can provide strong security, scalability, and operational flexibility. But cloud security is not automatic. Businesses still need to configure access properly, monitor activity, manage permissions, review third-party providers, and understand where sensitive data is stored.

One of the most common mistakes organizations make is assuming that using a cloud provider means security is fully handled by the provider. In reality, cloud security is often a shared responsibility. The provider may secure the infrastructure, but the business must still manage identity, access, permissions, data classification, configuration, logging, and user behavior. If a cloud environment is misconfigured, over-permissioned, poorly monitored, or connected to compromised accounts, sensitive data can still be exposed. The lesson is not that cloud systems are unsafe. The lesson is that cloud systems need active cybersecurity oversight.

Third-Party Risk Is Business Risk

Many modern breaches involve vendors, service providers, cloud platforms, software partners, managed services, consultants, or other third parties. Businesses often depend on outside providers to operate efficiently, but every external relationship can introduce cybersecurity risk. A third party may host sensitive data. It may manage cloud infrastructure. It may provide patient support services. It may process claims. It may maintain software. It may access internal systems. It may store backups. It may support billing, scheduling, research, or customer communications. If that third party is compromised, the business may still face the consequences. Patients, customers, regulators, investors, and partners may not separate the organization from its service providers. They simply know their data was affected.

This is why vendor risk management is essential. Organizations need to know which third parties have access to sensitive data, what security controls are in place, how incidents are reported, how data is protected, and what happens when a vendor or cloud provider experiences unauthorized activity. Third-party risk is not paperwork. It is a real cybersecurity exposure.

Material Cybersecurity Incidents Are a Leadership Issue

Amgen determined the incident was material, according to reporting based on its securities filing. This is important because material cybersecurity incidents are not just technical events. They become leadership, legal, operational, financial, and reputational issues.

A strong response plan helps answer critical questions. Who leads the response? Who contacts outside forensic experts? Who communicates with affected parties? Who evaluates legal and regulatory notification requirements? Who determines whether systems are contained? Who verifies whether data was accessed or stolen? Who manages business continuity? Who updates leadership? Without a plan, organizations lose time during the most critical phase of the incident.

Intellectual Property Theft

In biotech and pharma, intellectual property is often one of the organization’s most valuable assets. Research data, drug development information, clinical trial material, manufacturing processes, and proprietary business strategies can represent years of investment. When attackers steal intellectual property, the damage may not be immediately visible. Unlike ransomware that shuts down systems, IP theft can be quiet. The business may continue operating while sensitive research or proprietary files are already in the hands of an unauthorized party. That creates long-term risk. Stolen IP can affect competitive advantage, regulatory strategy, investor confidence, partnership negotiations, and future revenue.

Lessons Learned From the Amgen Incident

The Amgen breach should prompt businesses to review their own cybersecurity posture, especially if they handle sensitive health information, intellectual property, regulated data, or cloud-stored records. The first lesson is that cloud environments require continuous oversight and that third-party security matters. If external providers host or process sensitive data, the organization must evaluate their security practices, contracts, notification processes, access controls, and incident response procedures. Another lesson we can all take is that cybersecurity is now a boardroom and leadership issue. A breach can become material, public, and reputational. Leaders need visibility into risk before a crisis forces the conversation.

Proactive Assessments Are the Way Forward

A proactive cybersecurity assessment helps organizations understand where they are exposed before attackers find the gap. For healthcare and biotech businesses, this is especially important because the stakes are high.An assessment can review cloud security, access controls, user permissions, third-party risk, endpoint protection, backup readiness, compliance gaps, logging, data protection, phishing exposure, and incident response planning. It can identify weaknesses that may otherwise go unnoticed until an incident occurs. The goal is not to create fear. The goal is to create clarity and create a plan of action. Once an organization understands its risks, it can prioritize improvements and build a stronger defense.